SEP 11, 2015 10:08 PM PDT

AML Answer

WRITTEN BY: Ilene Schneider
A protein domain may be critical to helping patients fighting acute myeloid leukemia (AML) avoid a relapse. Researchers at Rice University, working with colleagues at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center, have developed a small molecule that could deliver a “one-two punch” to proteins that resist chemotherapy in patients with AML.

Small molecule helps patients fight acute myeloid leukemia.

Called STAT3, the protein interferes with chemotherapy by halting the death of cancerous cells and enabling them to grow. The molecule discovered at Rice finds and then attacks a previously unknown binding site on STAT3, disrupting its disease-promoting properties. The work led by Rice chemist Zachary Ball, Baylor pediatrician Michele Redell and MD Anderson oncologist David Tweardy appears in the journal Angewandte Chemie and is reported in Bioscience Technology

An earlier discovery by Ball’s lab led to the discovery and exploitation of this new drug target. That discovery enabled researchers to identify, on a molecular level, the target of action for drug molecules by using rhodium-based inorganic complexes. The complexes recognize specific folds in a protein chain and catalyze minute changes in those sequences, thus forming a “tag” for later analysis.

The STAT3 protein (“signal transducer and activator of transcription 3″) is a suspected culprit in the relapse of nearly 40 percent of children who have AML. The new proximity-driven rhodium(II) catalyst known as MM-206 seeks and modifies an inhibitor-binding site on the protein and delivers the inhibitor, naphthalene sulfonamide, to the modified site.

According to Ball, “This is the confluence of two ideas we’ve been working on around what you can do with conjugates linked to rhodium.”

Redell, who is also part of the leukemia and lymphoma teams at Texas Children’s Hospital, added, “We know that increased activity of STAT3 in AML and other cancers helps the cancer cells survive chemotherapy, so any new strategy we can develop to stop that process could mean real benefit for our patients.”

Ball explained that STAT3 has been a target for scientists trying to shut down cancer cells, saying, ”STAT fits in the broad category of what are called ‘undruggable protein-protein interactions.’ There’s a large surface area with weak interactions for which we have typically failed to find good drugs.”

Prior research revolved around only one region of STAT3, its SH2 domain, with limited success. Ball added, “There’s no evidence people have tried to go after the coiled coil as a drug target. Our main advance, from a medicinal perspective, is that this compound also works in a mouse model. All the other compounds worked in cells, but in mice, they weren’t potent enough or stable enough. The discovery raises new questions about STAT3 biology and points the way to future anti-cancer approaches, including combination therapies of coiled-coil STAT3 inhibitors in tandem with other agents.”
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
FEB 08, 2021
Microbiology
Fecal Transplants May Improve Cancer Treatment Efficacy
FEB 08, 2021
Fecal Transplants May Improve Cancer Treatment Efficacy
Humans carry around trillions of microbes, and the ones in our guts - the gut microbiome - plays an essential role in ou ...
FEB 16, 2021
Clinical & Molecular DX
What Dead Cells Can Tell Us About Our Health
FEB 16, 2021
What Dead Cells Can Tell Us About Our Health
Taking a sample of tissue called a biopsy from an organ suspected of harboring a pathology is a common diagnostic practi ...
MAR 04, 2021
Clinical & Molecular DX
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
MAR 04, 2021
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
A newly-developed tool could help physicians monitor the performance of colorectal cancer therapies simply by examining ...
MAR 15, 2021
Cell & Molecular Biology
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
MAR 15, 2021
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
Cells are packed full of organelles and molecules like proteins floating in a liquid known as cytoplasm. In recent years ...
MAR 29, 2021
Cancer
Modeling metastasis
MAR 29, 2021
Modeling metastasis
Novel research published in Genome Biology investigates the cellular mechanisms at work during cancer metastasis using n ...
MAY 03, 2021
Cardiology
Task Force IDs 7 Costly Medical Procedures With No Benefit
MAY 03, 2021
Task Force IDs 7 Costly Medical Procedures With No Benefit
Researchers have identified a surprising number of health screens that are given to patients who may not need them. Thes ...
Loading Comments...